- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00407251
Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy
A Phase II Study of Patupilone (EPO906A) as a Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prostate cancer is the most common cancer diagnosed and the second most common cause of cancer death in men in North America (Jemal 2003). Many patients with localized disease have an excellent long-term survival and high cure rates with standard approaches (D'Amico 1998). However, patients with high risk, locally advanced and metastatic disease have a poor prognosis, and although hormonal therapy in the form of medical or surgical castration can induce significant long-term remissions,development of androgen independent disease is inevitable. Androgen independent (AI) disease, also termed hormone refractory prostate cancer (HRPC), is clinically detected by a rise in prostate specific antigen (PSA) and worsening of symptoms. Once patients reach this stage, therapeutic options are limited and prognosis is poor
Patients with hormone refractory prostate cancer after docetaxel chemotherapy have limited treatment options and no treatment has been proven to be efficacious. Because of the mechanism of action and the activity of anti-microtubule agents and combinations in general for HRPC, patupilone has potential for therapeutic activity in patients with HRPC that have progressed after first line docetaxel chemotherapy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T4N 4N2
- Tom Baker Cancer Centre
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BC Cancer Agency - Vancouver Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8B 5C2
- Juravinski Cancer Centre
-
London, Ontario, Canada, N6A 4L6
- London Health Sciences Centre
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have histological or cytological diagnosis of adenocarcinoma of the prostate.
- Patients must have metastatic or locally recurrent disease.
- Patients must have documented evidence of PSA progression
- The PSA must be > 5 ng/mL at the time of study entry.
- ECOG performance status of 0, 1 or 2.
- Patients must have a life expectancy of at least 12 weeks in the judgment of the investigator.
- Chemotherapy: patients must have received prior docetaxel based chemotherapy (either as a single agent or in combination). Patients must have evidence of progression while receiving docetaxel based chemotherapy or within 6 months after the completion of docetaxel based chemotherapy. Prior adjuvant or neoadjuvant chemotherapy is permitted provided therapy was completed > 12 months prior to registration. Prior therapy with mitoxantrone or experimental non-cytotoxic chemotherapy is permitted (e.g. monoclonal antibodies, vaccine therapy, receptor tyrosine kinase inhibitors).
- Hormonal Therapy: Prior hormone therapy is permitted. Patients must be hormone refractory and have been previously and currently treated with androgen ablative therapy (medical or surgical castration). Therapy with LHRH agonist must continue for those prostate cancer patients already receiving this treatment at the time of enrollment. If the patient has discontinued the LHRH agonist, this must be restarted and the castrate level of testosterone must be present. Patients must have discontinued any use of non-steroidal antiandrogens (e.g. bicalutamide, nilutamide, flutamide) at least 6 weeks prior to initiation of protocol therapy.
- Radiation: Prior external beam radiation is permitted provided a minimum of 4 weeks has elapsed between the last dose and enrollment to the trial. Exceptions may be made for low dose, nonmyelosuppressive radiotherapy after consultation with the principal investigator. Prior strontium is not permitted. Patients must have had less than 30% of marrow bearing areas irradiated.
- Steroids: Current treatment with steroids are permitted provided the dose is less than or equivalent to a daily dose of prednisone of 20mg.
- Laboratory Requirements - within 7 days prior to enrollment Hematology: absolute granulocytes ≥ 1.5 x 109/Lplatelets ≥ 100 x 109/Lhemoglobin ≥ 90 g/L Biochemistry: bilirubin ≤ 1.0 x upper limit of normal serum creatinine ≤ 1.5 x upper limit of normal AST/ALT ≤ 2.5 x upper limit of normal
- Patient consent must be obtained according to local Institutional and/or University Human Experimentation Committee requirements.
- Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre.
Exclusion Criteria:
- Patients with a history of other invasive cancer, except adequately treated non-melanoma skin cancer or other solid tumours curatively treated with no evidence of disease for > 3 years.
- Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to Patupilone or other agents used in the study.
- Other serious intercurrent illness of medical condition that might be aggravated by protocol treatment including: myocardial infarction within 6 months prior to study entry congestive heart failure unstable angina active cardiomyopathy unstable ventricular arrhythmia uncontrolled hypertension uncontrolled psychotic disorders serious infections active peptic ulcer disease
- HIV-positive patients receiving combination anti-retroviral therapy
- Peripheral neuropathy > grade 1.
- Patients who have received treatment with other investigational agents or anti-cancer therapy < 21 days prior to date of protocol treatment.
- Patients receiving anticoagulation with warfarin (Coumadin®).
- Patients with grade ≥ 1 diarrhea.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
PSA response
|
Secondary Outcome Measures
Outcome Measure |
---|
Time to treatment failure
|
objective response rate
|
duration of response
|
time to PSA progression
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Kim Chi, MD, BC Cancer Agency - Vancouver Centre
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OZM-005/CEPO906A2402
- Protocol number CEP0906A2402
- OZM-005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hormone Refractory Prostate Cancer
-
University of California, IrvineBristol-Myers SquibbCompletedRecurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate CancerUnited States
-
DendreonCompletedHormone Refractory Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer MetastaticUnited States
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHormone Refractory Prostate Cancer | Metastatic Prostate CarcinomaChina
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate CancerUnited States
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
Spanish Oncology Genito-Urinary GroupAstellas Pharma Inc; Apices Soluciones S.L.CompletedHormone-refractory Prostate CancerSpain
-
Peking UniversityWithdrawnHormone Refractory Prostate CancerChina
-
Tianjin Medical University Cancer Institute and...UnknownHormone Refractory Prostate CancerChina
-
CytoVac A/SCompletedHormone-refractory Prostate CancerDenmark
-
Ascenta TherapeuticsCompletedHormone Refractory Prostate CancerUnited States
Clinical Trials on Patupilone
-
Novartis PharmaceuticalsCompletedPeritoneal Neoplasms | Ovarian Cancer | Fallopian Tube CancerUnited States, Greece, Canada, Finland, Italy, Spain, United Kingdom, France, Denmark, South Africa, Australia, Poland
-
Novartis PharmaceuticalsCompletedNon-small Cell Lung Cancer | Brain MetastasisUnited States
-
Novartis PharmaceuticalsWithdrawn
-
Novartis PharmaceuticalsCompletedHepatocellular CarcinomaUnited States, Hong Kong, Taiwan, Korea, Republic of
-
Novartis PharmaceuticalsCompleted
-
University of ZurichCompletedRecurrent Glioblastoma Planned for Reoperation
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedAdvanced MalignanciesUnited States
-
Novartis PharmaceuticalsCompletedAdvanced Solid TumorsUnited States
-
Novartis PharmaceuticalsCompletedSolid Tumors | Advanced MalignanciesUnited States